Alloy Therapeutics and Biogen Enter Collaboration and License Agreement for AntiClastic ASO Platform

Alloy Therapeutics announced a multi‑target collaboration and license agreement with Biogen for the use of Alloy’s proprietary AntiClastic™ antisense oligonucleotide (ASO) platform to advance novel antisense therapeutics across multiple undisclosed disease targets. Under the agreement, Biogen will apply Alloy’s platform to address longstanding challenges in antisense drug potency and therapeutic index, with Alloy receiving an upfront payment plus potential milestone and royalty payments tied to future products. The partnership combines Biogen’s experience in developing innovative medicines with Alloy’s antisense discovery capabilities, aiming to accelerate the development of next‑generation genetic medicines.

Learn More